Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has seen a decline in its stock price by -0.96 in relation to its previous close of 2.09. However, the company has experienced a -6.33% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-13 that New post hoc analysis of data from Lexicon’s (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
Is It Worth Investing in Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Right Now?
LXRX has 36-month beta value of 1.29. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for LXRX is 239.51M, and currently, short sellers hold a 8.91% ratio of that float. The average trading volume of LXRX on April 10, 2024 was 4.70M shares.
LXRX’s Market Performance
The stock of Lexicon Pharmaceuticals Inc (LXRX) has seen a -6.33% decrease in the past week, with a -4.61% drop in the past month, and a 35.29% gain in the past quarter. The volatility ratio for the week is 6.58%, and the volatility levels for the past 30 days are at 9.08% for LXRX. The simple moving average for the past 20 days is -10.76% for LXRX’s stock, with a 20.02% simple moving average for the past 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with Jefferies repeating the rating for LXRX by listing it as a “Hold.” The predicted price for LXRX in the upcoming period, according to Jefferies is $3 based on the research report published on March 07, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $10. The rating they have provided for LXRX stocks is “Overweight” according to the report published on August 12th, 2022.
JP Morgan gave a rating of “Neutral” to LXRX, setting the target price at $7 in the report published on January 29th of the previous year.
LXRX Trading at -12.72% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.37% of loss for the given period.
Volatility was left at 9.08%, however, over the last 30 days, the volatility rate increased by 6.58%, as shares sank -26.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.74% upper at present.
During the last 5 trading sessions, LXRX fell by -6.33%, which changed the moving average for the period of 200-days by -10.78% in comparison to the 20-day moving average, which settled at $2.28. In addition, Lexicon Pharmaceuticals Inc saw 35.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from COATS LONNEL, who purchase 90,000 shares at the price of $1.05 back on Nov 16 ’23. After this action, COATS LONNEL now owns 914,359 shares of Lexicon Pharmaceuticals Inc, valued at $94,797 using the latest closing price.
COATS LONNEL, the Chief Executive Officer of Lexicon Pharmaceuticals Inc, purchase 10,000 shares at $1.01 during a trade that took place back on Nov 10 ’23, which means that COATS LONNEL is holding 824,359 shares at $10,100 based on the most recent closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -142.53 for the present operating margin
- 0.71 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -144.88. The total capital return value is set at -0.87. Equity return is now at value -167.06, with -82.89 for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -1.61. The debt to equity ratio resting at 1.08. The interest coverage ratio of the stock is -13.11.
Currently, EBITDA for the company is -171.2 million with net debt to EBITDA at -0.5. When we switch over and look at the enterprise to sales, we see a ratio of 492.37. The receivables turnover for the company is 1.19for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.60.
Conclusion
To put it simply, Lexicon Pharmaceuticals Inc (LXRX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
